Assignee
HANMI PHARMACEUTICAL CO LTD
KR·27 granted patents·21 pending applications·45 citations·filing 1996–2025
Top patents by PatentIndex Score
48 records- 0187US11535629B2Dioxoloisoquinolinone derivatives and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2021·Granted Dec 27, 2022·2 cites·15 claims
- 0284US11883402B2Crystalline forms of a quinazoline compound and its hydrochloride saltsHANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Jan 30, 2024·3 cites·21 claims
- 0383US12390533B2Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method thereforHANMI PHARMACEUTICAL CO LTD·Filed 2022·Granted Aug 19, 2025·0 cites·14 claims
- 0482US6093814AProcess for preparation of cefdinirHANMI PHARMACEUTICAL CO LTD·Filed 1996·Granted Jul 25, 2000·38 cites·17 claims
- 0578US12018060B2Glucagon derivativesHANMI PHARMACEUTICAL CO LTD·Filed 2021·Granted Jun 25, 2024·0 cites·10 claims
- 0677US12508298B2Protein complex by use of a specific site of an immunoglobulin fragment for linkageHANMI PHARMACEUTICAL CO LTD·Filed 2022·Granted Dec 30, 2025·0 cites·20 claims
- 0777US12139455B2Polyethylene glycol derivative and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2022·Granted Nov 12, 2024·0 cites·16 claims
- 0876US12325698B2Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the sameHANMI PHARMACEUTICAL CO LTD·Filed 2022·Granted Jun 10, 2025·0 cites·8 claims
- 0973US12491258B2Method for preparing long-acting drug conjugate through preparation of intermediateHANMI PHARMACEUTICAL CO LTD·Filed 2023·Granted Dec 9, 2025·0 cites·20 claims
- 1073US12415842B2Immunostimulating IL-2 analogsHANMI PHARMACEUTICAL CO LTD·Filed 2023·Granted Sep 16, 2025·0 cites·5 claims
- 1173US2026092051A1Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the sameHANMI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 1270US10696675B2Imidazopyridopyrimidine derivative compound and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2017·Granted Jun 30, 2020·1 cites·12 claims
- 1364US2025353831A1Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising sameHANMI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1463US2025276044A1COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASEHANMI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1562US2025099574A1Coronavirus vaccineHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1662US2025114463A1Liver-targeted drug and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1761US12274750B2Lyophilized formulation of long-acting human growth hormone immunoglobulin conjugateHANMI PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 15, 2025·0 cites·7 claims
- 1861US2024423979A1Therapeutically effective combination of a flt3 inhibitor and a bcl-2 inhibitor for the treatment of acute myeloid leukemiaHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1961US2025121086A1Liver-targeted substance and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2061US2024293512A1Therapeutic use of combination including triple agonist having activities to all of glucagon, glp-1, and gip receptorsHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2159US12552850B2GLP-1/GIP dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising sameHANMI PHARMACEUTICAL CO LTD·Filed 2021·Granted Feb 17, 2026·0 cites·24 claims
- 2259US2024082355A1Liquid formulation of protein and methods of preparing the sameHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2359US2025268922A1Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitorHANMI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2458US2025032420A1Method for preparing oral composite tablet containing proton pump inhibitor and antacid and oral composite tablet prepared therebyHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2558US2024197834A1Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivativeHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2657US2025042914A1Pikfyve kinase inhibitorHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2757US2024301433A1Non-natural 5'-untranslated region and 3'-untranslated region and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2856US2024285731A1Efpeglenatide to reduce risk of developing cardiovascular disease or renal dysfunctionHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2955US2024067613A1Novel quinazoline derivatives as sos1 inhibitors and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3054US12558431B2Method of preparing protein conjugateHANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Feb 24, 2026·0 cites·13 claims
- 3154US2024299500A1Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndromeHANMI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3252US12090248B2Crosslinked hyaluronic acid, hyaluronic acid hydrogel, and method for producing crosslinked hyaluronic acid and hyaluronic acid hydrogelHANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 17, 2024·0 cites·14 claims
- 3352US2024325311A1Oral complex tablet comprising sitagliptin, dapagliflozin, and metforminHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3450US12350265B2Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agentsHANMI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jul 8, 2025·0 cites·21 claims
- 3549US2024350590A1Composition for orally administered formulation containing glp-1 analogueHANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3649US2025257070A1Novel sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effectHANMI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 3748US12433867B2Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemiaHANMI PHARMACEUTICAL CO LTD·Filed 2020·Granted Oct 7, 2025·0 cites·11 claims
- 3848US10781217B2Imidazopyridazine compoundHANMI PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 22, 2020·0 cites·13 claims
- 3947US12479845B2Imidazopyridine derivative compounds and use of sameHANMI PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 25, 2025·0 cites·11 claims
- 4047US11925691B2Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugateHANMI PHARMACEUTICAL CO LTD·Filed 2018·Granted Mar 12, 2024·0 cites·3 claims
- 4146US12344618B2Heterotricyclic derivative compound and use of sameHANMI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jul 1, 2025·0 cites·12 claims
- 4245US12227510B2Crystal form of acid addition salt of furopyrimidine compoundHANMI PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 18, 2025·0 cites·5 claims
- 4344US12582636B2Pharmaceutical composite formulation comprising proton pump inhibitor and antacidHANMI PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 24, 2026·0 cites·7 claims
- 4443US12435328B2Therapeutic enzyme fusion protein having a novel structure and use thereofHANMI PHARMACEUTICAL CO LTD·Filed 2018·Granted Oct 7, 2025·0 cites·8 claims
- 4542US2024100087A1Pharmaceutical composition comprising proton pump inhibitor and antacidHANMI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4640US12319695B2Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effectHANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Jun 3, 2025·0 cites·3 claims
- 4740US10954232B2Pyrazole derivative as ALK5 inhibitor and uses thereofHANMI PHARMACEUTICAL CO LTD·Filed 2017·Granted Mar 23, 2021·0 cites·13 claims
- 4830US6528628B1Erythromycin a compounds and process for preparing the sameHANMI PHARMACEUTICAL CO LTD·Filed 1999·Granted Mar 4, 2003·1 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when HANMI PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →